ChronoScale completes Ekso Bionics sale and signs AI infrastructure deals targeting $1B run-rate by Q3 2027

EKSO BIONICS HOLDINGS, INC.

ChronoScale completed the sale of its Ekso Bionics business unit on September 30, 2026.
COO Jason C. Jones was terminated effective September 30, 2026, under a Severance Agreement with Ekso.
Severance includes a $243,750 lump sum, representing nine months of base salary, plus up to nine months of COBRA premiums.
ChronoScale signed an agreement with a new AI infrastructure customer and extended an existing customer contract, targeting $1B annualized run-rate revenue by Q3 2027.
ChronoScale terminated 5,852 shares of Series B Convertible Preferred Stock via a September 29, 2026 Withdrawal of Designation; no shares were outstanding.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.